EAU 2024 Prostate Cancer

Viewing 1-20 of 53 articles

EAU 2024: PSA Persistence After Radical Prostatectomy: Optimal Treatment in the Case of PSA Persistence

EAU 2024: Is All PSA Persistence Created Equal? Definition and Diagnostic Work-Up

EAU 2024: Synchronous mHSPC: What Are the Treatment Options and What Are the Goals of Treatment? What to Test Before Start of Hormonal Treatment and What to Monitor

EAU 2024: High-Risk Biochemical Recurrence After Radical Prostatectomy and Negative PSMA PET: What to Do? Systemic Therapy Alone

EAU 2024: High-Risk Biochemical Recurrence after Radical Prostatectomy and Negative PSMA PET: What to Do? The Guideline’s View

EAU 2024: State-of-the-Art Lecture: Local Therapy in mHSPC: Who Does Really Benefit?

EAU 2024: Negative Staging PSMA in High-Risk Disease: Can We Skip Extended Pelvic Lymph Node Dissection? Yes, We Can

EAU 2024: State-of-the-Art Lecture: Clinical and Molecular Stratification of Men with Biochemical Recurrence After Radical Prostatectomy

EAU 2024: Negative Staging PSMA in High-Risk Disease: Can We Skip Extended Pelvic Lymph Node Dissection? No, We Cannot

EAU 2024: Pelvic Lymph Node Dissection in Prostate Cancer: Update of the Limited vs. Extended Randomized Clinical Trial

EAU 2024: State-of-the-Art Lecture: How to Personalize Treatment in mHSPC? More than Just Counting Metastases

EAU 2024: Synchronous mHSPC: What Are the Treatment Options and What Are the Goals of Treatment? Germline Genetic Testing Necessary And/or Helpful?

EAU 2024: Synchronous mHSPC: What are the Treatment Options and What Are the Goals of Treatment? What Is the Evidence for Surgery?

EAU 2024: Synchronous mHSPC: What Are the Treatment Options and What Are the Goals of Treatment? What Is the Evidence for Systemic Therapy in Synchronous Low-Volume mHSPC

EAU 2024: Living with a Prostate Cancer Patient: Real-World Evidence from the Unprecedented Europa Uomo Prostate Cancer Partners in Europe Research (EU-ProPER) Study

EAU 2024: State-of-the-Art Lecture: Staging High-Risk Prostate Cancer with PSMA PET: Strengths and Pitfalls

EAU 2024: Efficacy of Transrectal and Transperineal Prostate Biopsy in Detecting Clinically Significant Prostate Cancer: Results of the ProBE-PC Randomised Clinical Trial

EAU 2024: Risk Adapted Screening for Prostate Cancer in Europe: PSA + MRI + Targeted Biopsies Only (Gothenburg-2 Trial)

EAU 2024: Risk Adapted Screening for Prostate Cancer in Europe: PSA + MRI (OPT - the Swedish Nationwide Screening Strategy)

EAU 2024: Synchronous mHSPC: What Are the Treatment Options and What Are the Goals of Treatment? What Is the Evidence for Radiotherapy

1
2
3